Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02662036 · ClinicalTrials.gov registry record · Phase 4
Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction
A Phase 4 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
NCT02662036 is a Phase 4 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 70 participants.
The verdict
NCT02662036, a Phase 4 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of analgesia provided by liposomal bupivacaine (Exparel) when compared to bupivacaine HCL as a transverse abdominis plane (TAP) block in terms of discharge milestones, opioid use, costs, and patient-reported satisfaction at 12, 24, and 72 hours. The investigators propose that Exparel will lower opioid use, length of stay, and overall cost of abdominally-based autologous breast reconstruction, and will lead to greater patient satisfaction.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Bupivicaine HCL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2018-03-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02662036
The ClinicalTrials.gov registry entry for NCT02662036 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal bupivacaine is the first listed.
NCT02662036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02662036 about?
NCT02662036 is a clinical study titled "Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction". This study will evaluate the efficacy of analgesia provided by liposomal bupivacaine (Exparel) when compared to bupivacaine HCL as a transverse abdominis plane (TAP) block in terms of discharge milestones, opioid use, costs, and patient-reported satisfaction at 12, 24, and 72 hours. The investigator...
What is the current status of trial NCT02662036?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2016-02-29. Estimated completion is 2018-03-08.
What interventions are being tested in trial NCT02662036?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Bupivicaine HCL (DRUG).
Who is sponsoring clinical trial NCT02662036?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.